Our Take
A 70% response rate in 154 heavily pretreated patients is real clinical data, but SMC approval for 44 patients per year in Scotland is a regional funding decision, not evidence of broader efficacy or cost-effectiveness across larger populations.
Why it matters
Multiple myeloma patients exhaust standard options after repeated relapses, and access to mechanistically distinct therapies (like GPRC5D-targeting agents) expands clinician options in a disease with high unmet need in later treatment lines. Scottish adoption signals regulatory confidence but does not predict NHS England uptake or international reimbursement.
Do this week
Healthcare economics teams: cross-reference SMC's full health economic assessment and MonumenTAL-1 trial data against your own population cohorts before projecting budget impact; the 44-patient-per-year estimate is Scotland-specific and uptake may diverge with clinical experience.
Scotland funds bispecific antibody for multiply relapsed myeloma
The Scottish Medicines Consortium has accepted talquetamab (Talvey) for use in NHS Scotland for adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and show disease progression on their last treatment. Johnson & Johnson welcomed the decision. Talquetamab is a bispecific antibody that binds GPRC5D on myeloma cells and redirects CD3+ T cells to attack the malignant population.
SMC estimates around 44 eligible patients per year in Scotland would benefit, with uptake expected to rise as clinical experience accumulates. The company notes that heavily pre-treated patients face high unmet need, as relapse becomes more frequent and treatment options narrow after each line of therapy.
MonumenTAL-1 study forms the evidence base
The approval rests on the pivotal phase 1/2 MonumenTAL-1 trial cohort (n=154) treated with talquetamab 0.8 mg/kg every other week. Overall response rate was 70 percent (company-reported), with deep and durable responses observed after a median follow-up of 23.4 months (company-reported). SMC considered these results clinically meaningful in a population characterised by treatment resistance. No independent third-party benchmark or reproducer of these efficacy figures was cited in the announcement.
Mechanism matters more than market size
Multiple myeloma is incurable, and most patients will relapse and require further therapy. Each successive line of treatment encounters resistance, and the range of approved options dwindles. A bispecific targeting GPRC5D (highly expressed in myeloma but distinct from CD38 and other standard targets) offers clinicians a mechanistically orthogonal choice for patients who have exhausted or become refractory to prior classes.
The 44-patient-per-year estimate for Scotland is modest and reflects the late-line, heavily pre-treated population. Broader UK and European adoption will depend on health economic assessments, budget impact modeling, and real-world response rates as clinical experience accumulates beyond the trial population. SMC approval does not guarantee England's National Institute for Health and Care Excellence (NICE) endorsement or rapid international uptake.
What to watch before widening use
Clinical teams should audit treatment sequencing protocols to identify which patients meet the strict eligibility criteria (three or more prior lines including the specified agent classes) and track response durability in your own cohorts. Health economic leads should obtain the full SMC assessment and MonumenTAL-1 publication (when available) to validate cost-per-response assumptions for your jurisdiction's reimbursement model. Talquetamab uptake in Scotland will inform efficacy and safety signals for regulatory submissions elsewhere; collect real-world outcome data early if you deploy it.